Analysis of Serum Vitamin D and Major Histocompatibility Complex Class I-Related Chain a (Mica) Levels in Patients With Breast Carcinoma

Abstract

Introduction: Breast carcinoma is the most deadly cancer in women worldwide, with an incidence rate
of 26 cases per 100,000 women in Indonesia. Treatment and prognosis is very dependent on the stage of
breast carcinoma. Vitamin D can inhibit proliferation and invasive cancer cells, induction of differentiation,
apoptosis and promotion of angiogenesis. Major Histocompatibility Complex class I - related chain A
(MICA) plays a role in reducing the expression of NKG2D receptors in breast carcinomas so that they can
be targeted for treatment of breast carcinoma treatment. The aim of this study was to determine vitamin D
and MICA levels in serum patients with non-metastatic and metastatic breast carcinoma.
Method: We examined 86 samples of breast carcinoma patients (44 non-metastatic samples and 42
metastatic samples) with a range of 29 - 68 years old. Vitamin D levels were examined by the Enzyme
Linked Flourescent Assay (ELFA) method while the MICA levels were examined by Enzyme Linked
Immunoabsorbant Assay (ELISA).
Result: There were significant differences in mean vitamin D levels in non-metastatic and metastatic breast
carcinomas (29.88 ng/mlvs19.06 ng/ml; p <0.01).Serum MICA levels in patients with non-metastatic breast
carcinoma were lower (333.52 pg/ml) than in metastatic breast carcinoma
(333.52 pg/mlvs528.71 pg/ml; p<0.01).A negative correlation was found between vitamin D levels and
MICA in both groups (Pearson correlation, p: -0.58).
Conclusion: Metastatic breast carcinoma had lower vitamin D levels and higher serum MICA levels than
non-metastatic breast carcinoma.